Nicolas Goossens1, C Billie Bian2, Yujin Hoshida2. 1. Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, USA; Division of Gastroenterology and Hepatology, Geneva University Hospital, Geneva, Switzerland. 2. Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.
Abstract
PURPOSE OF REVIEW: Current clinical practice guidelines recommend regular hepatocellular carcinoma (HCC) surveillance with biannual ultrasound with or without serum alpha-fetoprotein uniformly applied to all patients with cirrhosis. However, clinical implementation of this one-size-fits-all strategy has been challenging as evidenced by very low application rate below 20% due to various reasons, including suboptimal performance of the surveillance modalities. RECENT FINDINGS: Newly emerging imaging techniques such as abbreviated MRI (AMRI) and molecular HCC risk biomarkers have increasingly become available for clinical evaluation and implementation. These technologies may have a potential to reshape HCC surveillance by enabling tailored strategies. This would involve performing optimized surveillance tests according to individual HCC risk, and allocating limited medical resources for HCC surveillance based on cost-effectiveness. SUMMARY: Tailored HCC surveillance could lead to achievement of precision HCC care and substantial improvement of the current dismal patient prognosis.
PURPOSE OF REVIEW: Current clinical practice guidelines recommend regular hepatocellular carcinoma (HCC) surveillance with biannual ultrasound with or without serum alpha-fetoprotein uniformly applied to all patients with cirrhosis. However, clinical implementation of this one-size-fits-all strategy has been challenging as evidenced by very low application rate below 20% due to various reasons, including suboptimal performance of the surveillance modalities. RECENT FINDINGS: Newly emerging imaging techniques such as abbreviated MRI (AMRI) and molecular HCC risk biomarkers have increasingly become available for clinical evaluation and implementation. These technologies may have a potential to reshape HCC surveillance by enabling tailored strategies. This would involve performing optimized surveillance tests according to individual HCC risk, and allocating limited medical resources for HCC surveillance based on cost-effectiveness. SUMMARY: Tailored HCC surveillance could lead to achievement of precision HCC care and substantial improvement of the current dismal patient prognosis.
Authors: O Simmons; D T Fetzer; T Yokoo; J A Marrero; A Yopp; Y Kono; N D Parikh; T Browning; A G Singal Journal: Aliment Pharmacol Ther Date: 2016-11-08 Impact factor: 8.171
Authors: Hashem B El-Serag; Fasiha Kanwal; Jessica A Davila; Jennifer Kramer; Peter Richardson Journal: Gastroenterology Date: 2014-01-23 Impact factor: 22.682
Authors: Amit G Singal; Jasmin A Tiro; Jorge A Marrero; Katharine McCallister; Caroline Mejias; Brian Adamson; Wendy Pechero Bishop; Noel O Santini; Ethan A Halm Journal: Gastroenterology Date: 2016-11-05 Impact factor: 22.682
Authors: Mengjun Wang; Ronald E Long; Mary Ann Comunale; Omer Junaidi; Jorge Marrero; Adrian M Di Bisceglie; Timothy M Block; Anand S Mehta Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-05-19 Impact factor: 4.254
Authors: Amit G Singal; Ashin Mukherjee; B Joseph Elmunzer; Peter D R Higgins; Anna S Lok; Ji Zhu; Jorge A Marrero; Akbar K Waljee Journal: Am J Gastroenterol Date: 2013-10-29 Impact factor: 10.864
Authors: Jeong Hee Yoon; Jeong Min Lee; Dong Ho Lee; Ijin Joo; Ju Hyun Jeon; Su Joa Ahn; Seung-Taek Kim; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon Journal: Liver Cancer Date: 2020-08-06 Impact factor: 11.740
Authors: Amit G Singal; Yujin Hoshida; David J Pinato; Jorge Marrero; Jean-Charles Nault; Valerie Paradis; Nabihah Tayob; Morris Sherman; Young Suk Lim; Ziding Feng; Anna S Lok; Jo Ann Rinaudo; Sudhir Srivastava; Josep M Llovet; Augusto Villanueva Journal: Gastroenterology Date: 2021-03-09 Impact factor: 33.883